Suzhou-based device maker ViVest Medical Technology Co., Ltd has reportedly raised “hundreds of millions” of RMB in a Pre-Series B financing round led by SDIC Unity Capital. Other investors included Dingxin Capital and Anji Liangshan State-owned Holdings. The proceeds will be used to advance a clinical study for its fully automatic wearable cardioverter defibrillator (WCD) and ramp up semi-automatic external defibrillator (AED) manufacturing capacity, multi-variety research, and development and overseas marketing layout.
Company Profile
Founded in 2019, ViVest Medtech is engaged in developing China’s first “active class III devices + data services” heartrate management platform against sudden cardiac death. Its WCD product entered a device review green channel in January 2021 and is on the brink of clinical trials. This innovative platform aims to provide comprehensive heart rate management solutions, enhancing patient outcomes and addressing critical needs in cardiovascular care.
Future Plans
With the new funding, ViVest Medtech plans to accelerate the development and commercialization of its WCD, a critical device for preventing sudden cardiac death. The company will also expand its AED manufacturing capabilities and enhance its research and development efforts to introduce a variety of new products. Additionally, ViVest will focus on expanding its overseas market presence, leveraging its technological advancements and innovative solutions.-Fineline Info & Tech
